Recently, Transmembrane protein 106B (TMEM106B) aggregates were described in the postmortem brain tissues of patients with a wide range of neurodegenerative diseases, including Alzheimer’s Disease (AD) [75], Parkinson’s Disease (PD) [19, 75], frontotemporal lobar degeneration (FTLD) [38, 75], amyotrophic lateral sclerosis (ALS) [9, 75], as well as other neurodegenerative diseases and normal aging [9, 75]. This evidence concerns the gene TMEM106B and frontotemporal dementia.